Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
Department of Health and Human Services — National Institutes of Health
Opportunity #: 4R44DA057133-02
Description
SBIR Phase Phase II award: "Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting." awarded to ENALARE THERAPEUTICS INC in PRINCETON, New Jersey. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,499,118. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.gov